Secukinumab treatment in rheumatoid arthritis is associated with incremental benefit in the clinical outcomes and HRQoL improvements that exceed minimally important thresholds

BACKGROUND: The primary aim of rheumatoid arthritis (RA) treatment is to induce remission, the absence of disease activity. The objective of this study was to explore the association between clinical endpoints used to gauge RA treatment efficacy and patient-reported outcomes of health-related qualit...

Descripción completa

Detalles Bibliográficos
Autores principales: Strand, Vibeke, Kosinski, Mark, Gnanasakthy, Ari, Mallya, Usha, Mpofu, Shephard
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4016279/
https://www.ncbi.nlm.nih.gov/pubmed/24597620
http://dx.doi.org/10.1186/1477-7525-12-31

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4016279/
https://www.ncbi.nlm.nih.gov/pubmed/24597620
http://dx.doi.org/10.1186/1477-7525-12-31

Ejemplares similares